Dai Yuhong, Feng Jin, Zhou Xiao
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2023 Jan 23;13:1091934. doi: 10.3389/fonc.2023.1091934. eCollection 2023.
Sweat gland carcinoma (SGC) is a rare neoplasm originating from sweat glands. Surgical resection is the first choice for SGC treatment, and there is no consensus on other treatments for advanced SGC.
In this case report, we present a case of a female patient with advanced SGC who received surgery; radiotherapy; multiple lines of chemotherapy, which include docetaxel, nedaplatin, albumin-bound paclitaxel, and pemetrexed; and immunotherapy (camrelizumab). The survival time of this patient is 35 months. MRI tumor monitoring indicated that these treatments slowed the progression of the disease. The effectiveness of chemotherapy, radiotherapy, and immunotherapy should be tested for more patients with SGC in the future.
Although the patient's tumor was uncontrolled eventually, multiple treatments delayed tumor growth over a period of time, providing ideas for others when choosing regimens.
汗腺癌（SGC）是一种起源于汗腺的罕见肿瘤。手术切除是SGC治疗的首选方法，对于晚期SGC的其他治疗方法尚无共识。
在本病例报告中，我们介绍了一名晚期SGC女性患者的病例，该患者接受了手术、放疗、多线化疗（包括多西他赛、奈达铂、白蛋白结合型紫杉醇和培美曲塞）以及免疫治疗（卡瑞利珠单抗）。该患者的生存时间为35个月。MRI肿瘤监测表明，这些治疗减缓了疾病的进展。未来应针对更多SGC患者测试化疗、放疗和免疫治疗的有效性。
尽管患者的肿瘤最终未能得到控制，但多种治疗在一段时间内延缓了肿瘤生长，为他人选择治疗方案提供了思路。
